Teligent, Inc.
Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | |
|---|---|---|---|---|---|---|
| Revenue | $7.4M | $13.1M | $14.5M | $17.7M | $63.0M | $44.3M |
| Operating income | −$18.1M | −$2.7M | −$3.5M | $3.0M | $2.5M | −$3.2M |
| Net income | −$26.8M | −$8.7M | −$4.8M | $831,000 | −$12.0M | $6.7M |
| Total assets | $87.8M | $206.9M | $190.9M | $184.6M | $183.2M | $180.7M |
| Total liabilities | $197.9M | $212.2M | $172.5M | $139.8M | $126.6M | $114.0M |
| Equity | −$110.2M | −$5.3M | $18.4M | $44.8M | $56.7M | $66.8M |
| EPS (diluted) | $-4.98 | $-1.62 | $-0.09 | $0.02 | $-0.02 | $-0.07 |
| Shares out. | 53.9M | 53.8M | 53.5M | 53.2M | 53.0M | 52.8M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2020- Operating margin
- −242.4%
- Net margin
- −360.4%
- Return on equity
- 24.4%
- Return on assets
- −30.6%
- Return on capital (ROCE)
- −27.9%
- Liabilities / assets
- 225.5%
- Debt / equity
- —
- Book value / share
- $-2.04
- Revenue growth (YoY)
- −43.2%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2020- Altman Z″ (distress)
- -9.43distress
- Accruals / assets
- −11.5%clean
- Piotroski F-Score
- 2/9weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 3 severe● 5 warning● 2 good- Negative shareholder equity
- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Operating losses (negative operating margin)
- Reported a net loss
- Revenue declined year-over-year
- High leverage (liabilities > 70% of assets)
- Negative operating cash flow
- Strong return on equity (>15%)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Qmissed a reporting deadline ↗May 17, 2021
- NT 10-Kmissed a reporting deadline ↗Mar 31, 2021
- NT 10-Qmissed a reporting deadline ↗Nov 13, 2020
- NT 10-Qmissed a reporting deadline ↗Aug 14, 2020
- NT 10-Kmissed a reporting deadline ↗Mar 30, 2020
- NT 10-Kmissed a reporting deadline ↗Mar 19, 2019
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
FDA-approved drugs
openFDA · most recent- FLURANDRENOLIDEDec 30, 2016
- DOBUTAMINE HYDROCHLORIDEFeb 21, 1995
- CEFOTANApr 29, 1993
- DOPAMINE HYDROCHLORIDEJun 28, 1983
- M.V.I.-12 LYOPHILIZED—
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Yachmetz Philip KOfficer — EVP, Chief Legal Off, Corp Sec | Jul 16, 2021 | Option exercise | 7,835 | $0.00 |
| Pate R CarterDirector | May 27, 2021 | Buy | 30,000 | $0.55 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Material events
SEC Form 8-K · most recent- Entered a material agreement · Bankruptcy or receivership · New financial obligation · Debt acceleration / triggering event · Delisting / listing-standard notice · Director / officer change · Regulation FD disclosureOct 15, 2021
- Director / officer changeSep 27, 2021
- Modified shareholder rights · Amended charter or bylawsSep 24, 2021
- Shareholder voteJul 22, 2021
- Results of operationsMay 4, 2021
- Delisting / listing-standard noticeApr 22, 2021
- Delisting / listing-standard noticeApr 15, 2021
- Director / officer changeApr 15, 2021
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- SC 13G/AFeb 14, 2022
- 25-NSEOct 27, 2021
- 8-KFORM 8-KOct 15, 2021
- 3PRIMARY DOCUMENTOct 8, 2021
- 3PRIMARY DOCUMENTOct 7, 2021
- 8-KFORM 8-KSep 27, 2021
- 8-KFORM 8-KSep 24, 2021
- 10-QAug 16, 2021
- 4OWNERSHIP DOCUMENTJul 22, 2021
- 4OWNERSHIP DOCUMENTJul 22, 2021
- 4OWNERSHIP DOCUMENTJul 22, 2021
- 8-KFORM 8-KJul 22, 2021
- 4PRIMARY DOCUMENTJul 22, 2021
- 4PRIMARY DOCUMENTJul 22, 2021
- 4/APRIMARY DOCUMENTJul 20, 2021
Event-driven situations (3)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.